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52 Poster Session-Iconducted a retrospective cohort study to describe the risk factors
and natural history of post-transplant DM and HTN. Consecutive
allogeneic HCT recipients from 2003–2005 were included in this
study if they had survived .1 year post-transplant and had not
received a previous HCT. DM and HTN were defined by published
adult and pediatric guidelines. The final cohort consisted of 180
patients (adult [$18 years] 106, pediatric [\18 years] 74); the median
age was 27 (range 0.2–69) years. Before HCT, 13% had DM, 9% had
HTN, 18% smoked and 19% were obese. Pediatric patients were
less likely to have pre-transplant DM, HTN, smoking history or
high-risk disease and more likely to receive myeloablative (MA)
conditioning. MA conditioning (Cy 1 1320 cGy TBI 6 Flu) was
given to 66% recipients, remainder received non-MA conditioning
(Cy 1 Flu 1 200 cGy TBI). All patients are followed until at least
2 years post-HCT at our center; among these 1 year survivors, 156
(87%) were alive at 2 years. Acute or chronic graft-versus-host dis-
ease occurred in 118 (66%) patients; of these, 34% received cyclo-
sporine (CSA) for .12 months and 47% received prednisone for
.12 months. Within 2-years after HCT, 54 (30%) had DM while
126 (70%) had HTN. Rates were similar for adult (DM 30%,
HTN 68%) and pediatric (DM 30%, HTN 73%) recipients. At 2
years post-HCT, 12% had persistent DM while 39% had persistent
HTN. Increasing cumulative dose of corticosteroids increased the
likelihood of having persistent DM at 2 years post-transplant (no ste-
roids 7%, # 0.25 mg/kg/d 13%, .0.25 mg/kg/d 27%, p 5 0.02);
such an association was not observed for HTN. On multivariate
analyses, risk factors for DM included history of DM pre-HCT (rel-
ative risk [RR] 5.0 [95% CI, 2.8–8.9]) and prednisone exposure (RR
2.4 [1.3–4.5]), while no predictive factors for resolution of post-
HCT DM were identified. CSA exposure was the only risk factor
for post-HCT HTN (RR 1.6 [1.1–2.5]), while history of HTN
pre-HCT was predictive for persistent HTN beyond 2 years (RR
3.07 [1.1–8.3]). DM and HTN are frequent among survivors of adult
and pediatric allogeneic HCT and can persist for an extended period
of time after transplantation. Continued monitoring and treatment
of DM and HTN is necessary in HCT survivors, especially if
survivors have been exposed to corticosteroids.135
MORTALITY OF HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
ADMITTED TO A MEDICAL INTENSIVE CARE UNIT (MICU) AS PREDICTED
BY THE HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY
INDEX (HCTCI)
Miller, S.M., Rossetti, J., Sahovic, E., Hilton, C., Lister, J. The Western
Pennsylvania Cancer Institute, Pittsburgh, PA
Introduction: Severity of illness scores validated in the critical
care setting are known to underestimate mortality in cancer patients.
We evaluated the Hematopoietic Cell Transplantation Comorbidity
Index (HCTCI) score (Sorror et al) as a predictor of mortality in
HCT recipients requiring intensive care.
Methods: A retrospective review of HCT recipients transplanted
between January 1, 1997, and March 1, 2007 was preformed. The
HCTCI score was calculated for each patient at the time of admis-
sion to the MICU. The primary endpoint was defined as survival
for seven days from the time of discharge from the MICU. Co-
variates analyzed included age, sex, conditioning regimen, need for
mechanical ventilation, use of vasopressors, time from transplant
to MICU admission, HCT type, and absolute neutrophil count
(ANC) at the time of MICU admission.
Results: Seventy-four of 892 patients (8.3%) required MICU
care. Forty-two (57%) were males, 32 (43%) females and the median
age was 47 (range: 22–71). Twenty-three (31%) patients received
autologous, 26 (35%) matched related donor (MRD) and 25 (34%)
matched unrelated donor (MUD) HCT. Overall mortality was
72%. Using the Wilcoxon signed-rank test, the HCTCI score was
found to be highly predictive of mortality (p\0.0001). None of the
patients with an HCTCI score of $10 survived. Univariate analysis
identified transplant type [mortality: autologous 52%, MRD 73%,
MUD 88%; p 5 0.02], conditioning [mortality: myeloablative
91% versus non-myeloablative 57%; p5 0.002], mechanical ventila-
tion (MV): [mortality: MV n5 43, 79% versus no MV n5 31, 61%;
p5 0.0003], and ANC [mortality:\500 /mL 88%, ANC$ 500 /mL
60%; p5 0.01] as correlating with mortality. In multivariate analysis
only the HCTCI score remained significantly correlated withmortality (p 5 0.001) with a point estimate of the odds ratio of 2.8
(95% C.I. 1.5–5.3).
Conclusion: This retrospective study demonstrates the predictive
value of the HCTCI for mortality when calculated on admission to
the MICU at our institution. The HCTCI score is easily calculated
and readily applicable in the clinical setting. Prospective study of
the HCTCI is needed for validation of this tool as a predictor of
mortality on MICU admission.136
UTILITY OF THE PSYCHOSOCIAL ASSESSMENT OF CANDIDATES FOR
TRANSPLANTATION (PACT) SCALE IN ALLOGENEIC BMT
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1Cleveland
State University, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
The Psychosocial Assessment of Candidates for Transplantation
(PACT) scale was completed on 120 allogeneic BMT patients pre-
transplant, from 11/2003 to 6/2007. The PACT has 8 items, each
rated on a 5-point scale, and an initial and final rating independently
based on the rater’s overall impressions of the candidate’s accepta-
bility for transplant. This study assessed utility of the PACT scale
for psychosocial screening in allogeneic BMT. Examined were asso-
ciations of the eight PACT subscales and the final rating with
medical outcomes, post-transplant. Significant relationships (P #
0.05) between PACT subscales and medical outcomes are as follows:
better scores on compliance with medications and medical advice as-
sociates with lower in-hospital mortality, shorter length of stay and
readmission duration, and faster neutrophil and platelet engraft-
ment; better scores on drug/alcohol use associates with faster platelet
engraftment; better scores on family/support system availability and
on relevant knowledge and receptiveness to education associates with
decreased risk of mortality. The final rating score and medical
outcomes are not significantly related; however, study findings
underscore the prognostic value of the PACT subscales and, thus,
utility for screening of BMT candidates.137
ETHICAL REASONING ABOUT PATIENT ELIGIBILITY IN ALLOGENEIC BMT
BASED ON PSYCHOSOCIAL CRITERIA
Foster, L.W.1, McLellan, L.J.2, Rybicki, L.A.2, Bolwell, B.J.2 1Cleveland
State University, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH
Chairpersons of hospital ethics committees (HEC) and BMT
clinicians were compared regarding willingness to proceed with
allogeneic BMT given select psychosocial risk factors. A self- admin-
istered questionnaire was sent to 62 HEC chairpersons at hospitals
with an accredited BMT Program; response rate was 37%. Items in-
cluded background information, followed by six case vignettes from
a 2006 national survey on which BMT physicians, nurses, and social
workers agreed not to proceed with allogeneic BMT based on the fol-
lowing risk factors: suicidal ideation; use of addictive, illicit drugs;
history of non-compliance; has no caregiver; is alcoholic; and has
mild dementia. Opinions regarding transplant differed on one case
only, patient with mild dementia; 27% of HEC chairpersons recom-
mended not proceeding with BMT, which was significantly lower
than nurses (68%, p\ 0.001), physicians (63.5%, p\ 0.001), and
social workers (51.9%, P5 0.05). That HEC chairpersons disagreed
with BMT clinicians in the case of mild dementia may suggest that
they view dementia patients as more deserving of consideration for
BMT than patients who have some element of choice in the psycho-
social risk factor. In general, qualitative data reveal patterns of infor-
mal ethical reasoning that suggest transplant decisions may be linked
to patient responsibility for the psychosocial risk factor as well as
medical benefit/outcome.138
AVASCULAR NECROSIS (AVN) IN SURVIVORS OF HEMATOPOIETIC-
CELL TRANSPLANTATION (HCT): A LARGE SINGLE INSTITUTION
STUDY
McAvoy, S., Mulrooney, D.A., Arora, M., Baker, K.S., Burns, L.J.,
Majhail, N.S. University of Minnesota, Minneapolis, MN
AVN is a debilitating complication of HCT. We describe a con-
temporary cohort of patients with AVN after HCT to describe its
Poster Session-I 53presentation, treatment and risk-factors. AVN was defined as the
presence of joint symptoms with confirmatory radiological findings
on X-ray, CT or MRI at any time after HCT. Among 3527 HCT
recipients from 1990–2007, 73 (2.1%) cases of post-HCT AVN
were identified; of these, 8 (0.7%) occurred after autologous and
65 (2.7%) after allogeneic HCT (sibling 33, unrelated 19, umbilical
cord blood 13). Median age at HCT for cases was 29 (range, 4–60)
years and included 23% pediatric recipients (\18 years). Median fol-
lowup was 7 (range, 1–16) years. Myeloablative conditioning was
used in 74% and 77% received total body irradiation (TBI). Acute
and chronic graft-versus-host disease (GVHD) occurred in 69%
and 65%, respectively. Use of prednisone (or equivalent) was very
prevalent; 8% had received no prednisone, 23% had received a cumu-
lative dose of #0.5 mg/kg/day, and 69% had received .0.5 mg/kg/
day prior to diagnosis of AVN. AVN affected 155 joints in these 73
patients (median number of joints involved 2 [range, 1–6]) and was
diagnosed at a median of 18 months (interquartile range 11–33
months) post-HCT. Proximal femur (54%) and distal femur (36%)
were the most common sites. Association Research Circulation
Osseous stage, which classifies progressively worsening radiological
abnormalities and amount of bone involvement from stage 0–4,
could be assigned for 52 cases; of these, stage 3 or 4 (that requires sur-
gical intervention) was present in 60%. Thirty-five (48%) received
surgical treatment for AVN, among which joint replacement was
performed in 31 patients. Risk factor analysis was performed using
a randomly selected cohort of 148 HCT recipients frequency
matched by age, gender and year of HCT and with no joint symp-
toms. Risk of AVN was higher in allogeneic HCT recipients (odds
ratio (OR) 2.7 (95% CI, 1.2–6.2), P5 0.01) and with exposure to cor-
ticosteroids (OR 15.9 (6.5–39.1), p\ 0.01); diagnosis, conditioning
intensity and use of TBI did not increase its risk. In conclusion, AVN
is a relatively rare complication of HCT, typically occurs within the
first 3 years after HCT, presents with advanced stages and frequently
requires surgical management. Allogeneic HCT recipients, espe-
cially those exposed to corticosteroids, are at highest risk and may
benefit from screening for early detection and treatment to avoid
joint replacement surgery.139
DIAGNOSIS OF MENTAL HEALTH DISORDER DOES NOT EFFECT
OUTCOME IN ALLOGENEIC BONE MARROW TRANSPLANT
Khan, G.1, Sproat, L.2, Bolwell, B.2, Rybicki, L.2, Kalaycio, M.2,
Dean, R.2, Sobecks, R.2, Pohlman, B.2, Andresen, S.2, Sweetenham, J.2,
Copelan, E.2 1Cleveland Clinic Medicine Institute, Cleveland, OH;
2Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Background: Psychiatric disturbance before allogeneic stem cell
transplant (allo-SCT) has been associated with worse survival and
quality of life and is used in predictive indices for transplant out-
come.
Methods:We report a retrospective study that analyzed 142 pa-
tients who underwent fully ablative allo-SCT between January
2005 and June 2008. Patients with mental health disorder
(MHDx) were identified from pre-transplant psychosocial assess-
ment and physician evaluation before transplant. Patients were as-
signed MHDx if they were taking psychotropic medication or
specific MHDx was documented. Wilcoxon rank sum and Chi-
square tests were used to compare patients with MHDx to patients
without MHDx. Outcomes between these groups were estimated
using the Kaplan-Meier method via the log rank test.
Results: We identified 41 patients with MHDx and 101 patients
without. The Wilcoxon rank sum test analysis showed that patients
with MHDx had a significantly longer period from diagnosis to
transplant (P 5 0.001). Patients with MHDx had an increased inci-
dence of acute graft versus host disease (AGVHD) (P 5 0.003),
but not chronic graft versus host disease (CGVHD) (P 5 0.30).
Kaplan-Meier analysis showed no significant statistical difference
in Relapse Mortality (RM) (0.31), Non-Relapse Mortality (NRM)
(P 5 0.41) or Overall Survival (OS) (P 5 0.99). (See table below.)
One and two-year survival for patients with MHDx (56.2% and
47.2% respectively) and without MHDx (57.2% and 44.2% respec-
tively) were not statistically significant.
Conclusion: Identifying comorbidities that have an impact on
post-transplant survival is crucial to improving transplant outcome.
While this study shows no statistical association between MHDx andOS, RM or NRM it demonstrates a significant association of MHDx
on time period from diagnosis to transplant and incidence of
AGVHD. Identifying patients with MHDx early in pre-transplant
staging and initiating appropriate treatment might reduce time to
transplant and AGVHD. Providing targeted psychosocial services
could lead to an overall improved quality of life. This study did
not indicate that MHdx leads to worse outcome. Further investiga-
tion into pre-transplant MHdx and its role in pre-transplant care
as well as in transplant is warranted.
No MHD MHDx P-valueMonths from Diagnosis to
Transplant (mean 1SD)9.9 1 14.6 19.1 1 23.0 0.001AGVHD 59 / 101 (58.4%) 33 / 41 (80.5%) 0.003
CGVHD 33 / 101 (32.7%) 9 / 41 (22.0%) 0.30
Non-Relapse Mortality 28 / 101 (27.7%) 14 / 41 (34.1%) 0.41
Relapse Mortality 22 / 101 (21.8%) 5 / 41 (12.2%) 0.31
Overall Survival 51 / 101 (51.5%) 22 / 41 (53.7%) 0.99140
ALLELIC VARIATION IN TP53 AND MDM2 DNA REPAIR GENES CONSTI-
TUTE GENETIC RISK FACTORS FOR LONG-TERM SURVIVAL IN ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Dupont, B.1, Malkki, M.2, Gooley, T.2, Wang, H.2, Zhao, L.P.2,
Bojesen, S.E.3, Petersdorf, E.W.2, Hansen, J.A.2 1Memorial Sloan Ketter-
ing Cancer Center, New York, NY; 2Fred Hutchinson Cancer Reserch
Center, Seattle, WA; 3Herlev University Hospital, Herlev, Denmark
The p53 tumor suppressor pathway plays a major role in tumor
development and cell survival. Germline single nucleotide poly-
morphisms (SNP)s in codon 72 of TP53 (Arg72Pro; rs1042522)
and in the promoter region of the ubiquitin ligase MDM2 (-309;
rs2279744) influence apoptotic activity in response to cellular
stress. In vitro studies have demonstrated that cells homozygous
for Arg72 in p53 have significantly increased apoptotic activity in
response to cellular stress, while cells homozygous for Pro72
have increase in cell cycle arrest and DNA repair. We recently in-
vestigated the impact of these two SNPs on survival after transplan-
tation from HLA 10/10 matched unrelated donors. In brief,
analysis of samples and clinical outcome data contributed by the
National Marrow Donor Program Research Sample Repository
and by the Center for International Blood and Marrow Transplant
Research, respectively, demonstrated that patients with two p53
72Pro alleles and at least one copy of the MDM2-309 G allele
had an increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.41). We now re-
port the results of a second independent cohort of donor-recipient
pairs tested for the same p53 and MDM2 SNPs. All patients were
treated at the Fred Hutchinson Cancer Research Center and repre-
sented 731 related and 669 unrelated pairs including HLA matched
and mismatched cases. We find that patients with two p53 72Pro
alleles and at least one copy of the MDM2-309 G allele had a signif-
icant increase in mortality risk compared to patients with 2 p53
72Pro alleles and zero G alleles at -309 (HR 5 1.35). These results
are consistent with our hypothesis that the combination of recipient
genotypes for p53 Arg72/Pro and SNP -309 MDM2 affects post
transplantation survival. Detailed analysis of other clinical outcome
data are currently in progress.141
TASTE DISORDERS AND ORAL CLINIC EVALUATION IN PATIENTS SUBMIT-
TED TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Boer, C., Miranda, E., Vogorito, A., Correa, M.E., de Souza, C. Hema-
tology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil; Hema-
tology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil;
Hematology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil;
Hematology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil;
Hematology and Blood Transfusion Center, Campinas, Sao Paulo, Brazil
Graft versus host disease can affect the oral cavity leading to mu-
cosal salivary gland damages and causing change in taste perception.
